Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.

Abstract

Erlotinib, a specific epidermal growth factor receptor tyrosine kinase inhibitor, is used to treat various metastatic cancers. It is known to cause an acneiform rash. Herein, we report a case where the rash spared the previous radiotherapy field. A limitation of this study is that it is an anecdotal case report. Further research into the pathologic process of the rash is warranted to understand the reason for its absence in the irradiated skin.

• Authors: Jayati Acharya, Calum Lyon, David M Bottomley
• Journal: Journal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 60 Issue 1 Pg. 154-7 (Jan 2009) ISSN: 1097-6787 [Electronic] United States
• PMID: 19103369 (Publication Type: Case Reports, Journal Article)

Chemical References

• Protein Kinase Inhibitors
• Quinazolines
• Erlotinib Hydrochloride

Topics

• Adult
• Carcinoma, Non-Small-Cell Lung (drug therapy, radiotherapy)
• Erlotinib Hydrochloride
• Folliculitis (chemically induced)
• Humans
• Lung Neoplasms (drug therapy, radiotherapy)
• Male
• Protein Kinase Inhibitors (adverse effects)
• Quinazolines (adverse effects)
• Skin (radiation effects)